<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Acadia Pharmaceuticals Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=51316></link><description><![CDATA[Acadia Pharmaceuticals Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Mon, 29 Jun 2026 12:48:04 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/06/12_1028147215_20260629091422_1920722516.png]]></url></image><language>ko-KR</language><item><title><![CDATA[DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1037507</link><description><![CDATA[SAN DIEGO--(Business Wire/Korea Newswire)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral ...]]></description><pubDate>Mon, 29 Jun 2026 09:34:22 +0900</pubDate></item></channel></rss>